// App-Quantinova.ai

P118 : Baseline Characteristics of and Early Outcomes in the First 200 Patients With Rheumatoid arthritis Treated With Filgotinib in a Prospective Observational Study

Researchers

Presenter

  • James Galloway

Principal Investigators

  • Karen Bevers

  • Patrick Verschueren

  • Roberto Caporali

  • Susana Romero Yuste

  • Jerome Avouac

  • Emilia Gvozdenovic

  • Kristina Harris

  • Monia Zignani

  • Gerd Burmester

Medical Centers

  • Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands

  • 5Neurology, University Hospital of Pontevedra Pontevedra Spain

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Centre for Robotics Research, King's College London, London, United Kingdom

  • Clinical Sciences and Community Health, University of Milan, Milan, Italy

  • Galapagos, Mechelen, Belgium

  • Rheumatology, UPMC University Paris, Paris, France

  • Department of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, Germany

Locations

  • Netherlands

  • Italy

  • Spain

  • Belgium

  • France

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Complement Factor B

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Observational

  • Prospective

Phase

  • IV

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved